Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Regulation of SH3PX1 by dNedd4-long at the Drosophila neuromuscular junction.

Wasserman SS, Shteiman-Kotler A, Harris K, Iliadi KG, Persaud A, Zhong Y, Zhang Y, Fang X, Boulianne GL, Stewart B, Rotin D.

J Biol Chem. 2019 Feb 1;294(5):1739-1752. doi: 10.1074/jbc.RA118.005161. Epub 2018 Dec 5.

PMID:
30518551
2.

Intermediate activity of midge antifreeze protein is due to a tyrosine-rich ice-binding site and atypical ice plane affinity.

Basu K, Wasserman SS, Jeronimo PS, Graham LA, Davies PL.

FEBS J. 2016 Apr;283(8):1504-15. doi: 10.1111/febs.13687. Epub 2016 Mar 11.

3.

Sleepless vigilance: "Stonewall" Jackson and the duty hours controversy.

Mackowiak PA, Billings FT 3rd, Wasserman SS.

Am J Med Sci. 2012 Feb;343(2):146-149. doi: 10.1097/MAJ.0b013e31823bbcdd.

PMID:
22173047
4.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R.

Hum Vaccin. 2009 Jan-Feb;5(1):33-40. Epub 2009 Jan 27.

PMID:
18670195
5.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11. Epub 2007 May 18.

PMID:
17881903
7.

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.

J Infect Dis. 2004 Nov 15;190(10):1745-54. Epub 2004 Oct 19. Erratum in: J Infect Dis. 2005 Jun 15;191(12):2161.

PMID:
15499528
8.

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB.

JAMA. 2004 Aug 11;292(6):709-15.

PMID:
15304468
9.

Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):48-60. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740955
10.

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740951
11.

Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers.

Edelman R, Wasserman SS, Bodison SA, Perry JG, O'Donnoghue M, DeTolla LJ.

Vaccine. 2003 Oct 1;21(27-30):4335-47.

PMID:
14505916
12.

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK.

Clin Immunol. 2003 Sep;108(3):241-7.

PMID:
14499247
13.

Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study.

Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID, Pietzak M, Ventura A, Thorpe M, Kryszak D, Fornaroli F, Wasserman SS, Murray JA, Horvath K.

Arch Intern Med. 2003 Feb 10;163(3):286-92.

PMID:
12578508
14.

Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Edelman R, Wasserman SS, Kublin JG, Bodison SA, Nardin EH, Oliveira GA, Ansari S, Diggs CL, Kashala OL, Schmeckpeper BJ, Hamilton RG.

Vaccine. 2002 Dec 13;21(3-4):269-80. Erratum in: Vaccine. 2003 Jun 2;21(19-20):2689.

PMID:
12450702
15.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

16.

Determinants of HIV-1 shedding in the genital tract of women.

Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, Weber K, Cohen M, Levine A, Minkoff H, Miotti P, Palefsky J, Young M, Reichelderfer P; DATRI Study Group; WIHS Study Group.

Lancet. 2001 Nov 10;358(9293):1593-601. Erratum in: Lancet 2002 Feb 16;359(9306):630.

PMID:
11716886
17.

Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Wang JY, Pasetti MF, Noriega FR, Anderson RJ, Wasserman SS, Galen JE, Sztein MB, Levine MM.

Infect Immun. 2001 Aug;69(8):4734-41.

18.

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.

Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI.

Infect Immun. 2001 Jun;69(6):3581-90.

19.

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA.

Am J Trop Med Hyg. 2000 Jun;62(6):681-5.

PMID:
11304054
20.

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr, Nichols R, Edelman R, Bridwell M, Monath TP.

Infect Immun. 2001 Feb;69(2):988-95.

21.

Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections.

Plaisance KI, Kudaravalli S, Wasserman SS, Levine MM, Mackowiak PA.

Pharmacotherapy. 2000 Dec;20(12):1417-22.

PMID:
11130213
22.

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G, Levine MM.

Clin Immunol. 2000 Nov;97(2):146-53.

PMID:
11027455
23.

Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. The Division of AIDS Treatment Research Initiative 009 Study Group.

Baron P, Bremer J, Wasserman SS, Nowicki M, Driscoll B, Polsky B, Kovacs A, Reichelderfer PS.

J Clin Microbiol. 2000 Oct;38(10):3822-4.

24.

Vibrio cholerae ACE stimulates Ca(2+)-dependent Cl(-)/HCO(3)(-) secretion in T84 cells in vitro.

Trucksis M, Conn TL, Wasserman SS, Sears CL.

Am J Physiol Cell Physiol. 2000 Sep;279(3):C567-77.

25.

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.

Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH.

Vaccine. 2000 May 8;18(22):2399-410.

PMID:
10738097
26.

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM.

Infect Immun. 2000 Mar;68(3):1196-201.

27.

Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA.

Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, Sztein MB, Levine MM.

Infect Immun. 1999 Dec;67(12):6424-33.

28.
29.

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.

Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, Losonsky GA, Alegria S, Levine MM.

J Infect Dis. 1999 Nov;180(5):1709-12.

PMID:
10515838
30.

Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.

Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM.

Pediatr Infect Dis J. 1999 Jul;18(7):624-30.

PMID:
10440439
31.

Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ.

Infect Immun. 1999 Apr;67(4):2030-4.

32.

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.

Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, Dulkerian S, West DJ, Gewolb IH.

Pediatrics. 1999 Feb;103(2):E14.

PMID:
9925860
33.

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.

AIDS. 1998 Jul 30;12(11):1291-300.

PMID:
9708408
34.

Effects of IFN-beta on human cerebral blood flow distribution.

Mackowiak PA, Siegel E, Wasserman SS, Cameron E, Nessaiver MS, Bever CT.

J Interferon Cytokine Res. 1998 Jun;18(6):393-7.

PMID:
9660246
35.

A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM.

Bull World Health Organ. 1998;76(1):63-71.

36.

Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.

Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM.

Lancet. 1998 May 16;351(9114):1472-6.

PMID:
9605803
37.

Goldfish, Carassius auratus, a novel animal model for the study of Mycobacterium marinum pathogenesis.

Talaat AM, Reimschuessel R, Wasserman SS, Trucksis M.

Infect Immun. 1998 Jun;66(6):2938-42.

38.

Detection of genital human papillomavirus and associated cytological abnormalities among college women.

Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W, Frost A, Tabara SO, Shah K.

Sex Transm Dis. 1998 May;25(5):243-50.

PMID:
9587175
39.

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ.

Infect Immun. 1997 Sep;65(9):3852-6.

40.

Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models.

Powell JL, Wright AC, Wasserman SS, Hone DM, Morris JG Jr.

Infect Immun. 1997 Sep;65(9):3713-8.

41.

Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM.

Infect Immun. 1997 Feb;65(2):452-6.

42.

No adverse impact on protection against pertussis from combined administration of Haemophilus influenza type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe.

Levine OS, Lagos R, Losonsky GA, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine MM.

J Infect Dis. 1996 Dec;174(6):1341-4.

PMID:
8940230
43.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

44.

Effects of anatomic site, oral stimulation, and body position on estimates of body temperature.

Rabinowitz RP, Cookson ST, Wasserman SS, Mackowiak PA.

Arch Intern Med. 1996 Apr 8;156(7):777-80.

PMID:
8615711
45.

Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.

Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM.

Pediatr Infect Dis J. 1996 Mar;15(3):216-22.

PMID:
8852909
46.

Antibodies that react with the capsular polysaccharide of Vibrio vulnificus are detectable in infected patients, and in persons without known exposure to the organism.

Fiore A, Hayat U, Wasserman SS, Wright A, Bush CA, Morris JG Jr.

Diagn Microbiol Infect Dis. 1996 Mar;24(3):165-7.

PMID:
8724403
47.

Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM.

Infect Immun. 1996 Jan;64(1):10-5.

49.

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM.

Vaccine. 1995 Nov;13(16):1488-94.

PMID:
8578831
50.

Physicians' perceptions regarding body temperature in health and disease.

Mackowiak PA, Wasserman SS.

South Med J. 1995 Sep;88(9):934-8.

PMID:
7660211

Supplemental Content

Loading ...
Support Center